# Stem Cell Transplant for Hematological Malignancy

> **NCT00176930** · NA · TERMINATED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 330 (actual)

## Conditions studied

- Leukemia, Myeloid, Chronic
- AML
- Leukemia, Lymphocytic, Acute
- MDS
- Leukemia, Lymphocytic, Chronic
- JMML
- Hodgkin's Disease
- Non-hodgkin's Lymphoma
- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** Stem Cell Transplant
- **DRUG:** Cyclophosphamide
- **RADIATION:** Total Body Irradiation
- **DRUG:** Busulfan
- **DRUG:** Equine ATG (ATGAM)
- **BIOLOGICAL:** CD4+/CD25+ cells

## Key facts

- **NCT ID:** NCT00176930
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-10
- **Primary completion:** 2019-12
- **Final completion:** 2019-12
- **Target enrollment:** 330 (ACTUAL)
- **Why stopped:** replaced by another study ; Trial re-written as MT2015-29
- **Last updated:** 2021-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00176930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00176930, "Stem Cell Transplant for Hematological Malignancy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00176930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*